缺血性卒中合并心房颤动患者抗凝使用的差异与时间趋势
FLiPER-AF卒中研究纳入2010至2016年24 040例缺血性卒中合并心房颤动病例,分析直接口服抗凝药、阿司匹林和华法林的使用差异。结果显示DOAC使用从0%增至36%,华法林从51%降至17%,阿司匹林稳定在42%-40%;黑人华法林处方几率高于白人,女性阿司匹林和华法林处方几率低于男性。
要点
- 2010至2016年DOAC使用从0%增至36%,华法林从51%降至17%。
- 黑人出院时华法林处方几率高于白人(OR 1.22;95%CI 1.07-1.40)。
- 女性出院时阿司匹林(OR 0.92;95%CI 0.86-0.98)和华法林(OR 0.91;95%CI 0.84-0.99)处方几率低于男性。
核心结论
- 研究证实DOAC使用增加、华法林使用下降,阿司匹林使用保持稳定。
- 缺血性卒中合并心房颤动患者抗凝使用存在性别和种族-民族差异。
研究设计与样本
- FLiPER-AF卒中研究纳入2010至2016年佛罗里达-波多黎各卒中登记中24 040例缺血性卒中病例。
- 采用多变量逻辑回归模型评估种族-民族和性别对DOAC、阿司匹林和华法林使用的影响,校正社会人口学、医院和临床因素。
主要发现
- 24 040例中女性占54%,黑人10%,佛罗里达西班牙裔12%,波多黎各西班牙裔4%,白人74%。
- 2010至2016年DOAC使用从0%增至36%,华法林从51%降至17%,阿司匹林从42%至40%。
- 校正后黑人华法林处方几率高于白人(OR 1.22;95%CI 1.07-1.40)。
- 男性阿司匹林(42.1% vs 38.8%)、华法林(33.6% vs 28.9%)和DOAC(21.3% vs 19.3%)使用率高于女性。
- 校正后女性阿司匹林(OR 0.92;95%CI 0.86-0.98)和华法林(OR 0.91;95%CI 0.84-0.99)处方几率低于男性,DOAC无性别差异。
临床怎么用
- 临床应关注缺血性卒中合并心房颤动患者中女性和黑人抗凝处方的差异。
- 需了解差异驱动因素以制定更好的房颤卒中预防实践策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Ischemic stroke (IS) secondary to atrial fibrillation (AF) is largely preventable with the use of anticoagulation. We sought to identify race-ethnicity and sex disparities with the use of direct oral anticoagulants (DOACs), aspirin, and warfarin in IS patients with AF and to identify temporal trends in the utilization of these medications. Methods- The FLiPER-AF Stroke Study (Florida Puerto Rico Atrial Fibrillation) included 24 040 IS cases enrolled in the Florida-Puerto Rico Collaboration to Reduce Stroke Registry from 2010 to 2016. Multivariable logistic regression models were performed to evaluate the effect of race-ethnicity and sex on utilization of DOACs, aspirin, and warfarin for stroke prevention in AF after adjustment for sociodemographic, hospital, and clinical factors. Results- Among 24 040 IS cases, 54% were women and 10% black, 12% FL-Hispanics, 4% PR-Hispanic, and 74% whites. From 2010 to 2016, DOAC use increased from 0% to 36%, warfarin use decreased from 51% to 17%, and aspirin use remained relatively stable (42%-40%). After adjustment, blacks had higher odds of warfarin (odds ratio, 1.22; 95% CI, 1.07-1.40) prescription at discharge compared with whites. Men had higher rates of aspirin (42.1% versus 38.8%), warfarin (33.6% versus 28.9%), and DOAC (21.3% versus 19.3%) use compared with women. After adjustment, women had lower odds of being discharged on aspirin (odds ratio, 0.92; 95% CI, 0.86-0.98) or warfarin (odds ratio, 0.91; 95% CI, 0.84-0.99). There was no sex difference in use of DOACs. Conclusions- Our study confirmed the increasing use of DOACs, downtrending use of warfarin, whereas aspirin use remained similar over the years. There are sex and race-ethnicity disparities in anticoagulation use in IS patients with AF. It is critical to understand underlying drivers of these disparities to develop better practice strategies for stroke prevention in patients with AF. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT03627806.
引用
- Sur NB, Wang K, Di Tullio MR, et al. Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation. Stroke. 2019. PMID: 31084325. doi:10.1161/STROKEAHA.118.023959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。